文献速递临床试验与 GCP

不可切除促纤维增生性黑色素瘤的抗PD-1治疗:2期SWOG S1512试验

Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial.
PubMed 文献 · Nat Med · 2025-08-14

SWOG S1512为两队列临床试验,评估帕博利珠单抗在促纤维增生性黑色素瘤中的活性。本文报告不可切除队列(B队列)单臂结果:27例患者接受帕博利珠单抗200 mg静脉注射每3周一次、最长2年,完全缓解率为37%(95%CI 19–58%),客观缓解率为89%(95%CI 71–98%)。

要点

  • 不可切除促纤维增生性黑色素瘤单药帕博利珠单抗完全缓解率37%(95%CI 19–58%),客观缓解率89%(95%CI 71–98%)。
  • 3年黑色素瘤特异性无进展生存率84%,总生存率96%,仅1例患者死于黑色素瘤进展。
  • 10例(37%)发生3级或4级不良事件,9例(33%)因不良事件终止治疗。

核心结论

  • 晚期促纤维增生性黑色素瘤对单药PD-1阻断治疗有高缓解率,支持单药抗PD-1作为首选治疗,但毒性发生频率在数值上高于其他患者人群。

研究设计与样本

  • SWOG S1512为两队列临床试验,本文报告B队列单臂临床试验,纳入27例不可切除促纤维增生性黑色素瘤患者,接受帕博利珠单抗200 mg静脉注射每3周一次、最长2年,主要终点为完全缓解率。

主要发现

  • 完全缓解率为37%(95%CI 19–58%),事后终点客观缓解率为89%(95%CI 71–98%)。
  • 估计3年黑色素瘤特异性无进展生存率为84%,总生存率为96%,仅1例患者死于黑色素瘤进展。
  • 10例(37%)发生3级或4级不良事件,9例(33%)因不良事件终止治疗。

临床怎么用

  • 作者认为单药抗PD-1可作为晚期促纤维增生性黑色素瘤的首选治疗,但毒性发生频率在数值上高于其他患者人群。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Desmoplastic melanoma is a distinct subtype of melanoma known to have preexisting immune infiltrates and high ultraviolet light damage, resulting in a high tumor mutational burden. We hypothesized that this may result in high response rates with single-agent anti-programmed death protein 1 (PD-1) therapy. SWOG S1512 was a two-cohort clinical trial testing the activity of pembrolizumab in patients with surgically resectable (cohort A) and unresectable (cohort B) desmoplastic melanoma. Here we report on the cohort B single-arm clinical trial, which enrolled 27 patients with unresectable desmoplastic melanoma receiving pembrolizumab 200 mg intravenously every 3 weeks for up to 2 years, with the primary endpoint of complete response rate. The complete response rate was 37% (95% confidence interval: 19-58%), and the post hoc endpoint of objective response rate was 89% (95% confidence interval: 71-98%). The estimated secondary endpoints of 3-year melanoma-specific progression-free survival and overall survival were 84% and 96%, respectively, with only one patient having died from melanoma progression. Ten patients (37%) experienced grade 3 or 4 adverse events, and nine patients (33%) discontinued treatment because of adverse events. Patients with advanced desmoplastic melanoma have a high response rate to single-agent PD-1 blockade therapy, supporting single-agent anti-PD-1 as the treatment of choice, but are limited by a frequency of toxicities that is numerically higher than in other patient populations. ClinicalTrials.gov identifier: NCT02775851.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Kendra KL, Bellasea SL, Eroglu Z, et al. Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial. Nat Med. 2025. PMID: 40813711. doi:10.1038/s41591-025-03875-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。